Coya Therapeutics, Inc. (COYA)
(Delayed Data from NSDQ)
$5.50 USD
-0.24 (-4.18%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $5.61 +0.11 (2.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Coya Therapeutics, Inc.'s return on equity, or ROE, is -61.05% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that COYA has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
COYA 5.50 -0.24(-4.18%)
Will COYA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for COYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COYA
Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy?
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates
COYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?
Other News for COYA
COYA forms 180 Bearish Setup on September 20
Is COYA ready to move higher? Stochastic Buy Signal shows up after rocketing 6.1%
Lower Bollinger Band Walk appears for COYA after 4.59% move
Coya Therapeutics, Inc. (COYA) Gets a Buy from Lake Street
COYA: Analyst Jason Kolbert Maintains 'Buy' Rating with $18 Target | COYA Stock News